Heeb M J, España F
Departments of Molecular and Experimental Medicine and of Vascular Biology, The Scripps Research Institute, La Jolla, CA.
Blood Cells Mol Dis. 1998 Dec;24(4):412-9. doi: 10.1006/bcmd.1998.0209.
Human glandular kallikrein (hK2) is a possible new marker for prostate cancer that is homologous to prostate specific antigen. Purified hK2 added to serum or plasma reacted with endogenous protease inhibitors to form complexes of >350, 135, and 80 kDa, and some hK2 remained free, as judged by immunoblotting. The former two complexes could be removed by specific antibodies to alpha2-macroglobulin and to C1- inactivator, respectively, and they comigrated on SDS-PAGE with complexes formed between hK2 and purified alpha2-macroglobulin or C1-inactivator. hK2 complexes of 80 kDa could not be completely removed with any anti-serpin antibody used. Thus, these may consist of more than one type of hK2 complex. In contrast, essentially all hK2 complexes were removed from seminal plasma by antibody to protein C inhibitor, demonstrating that protein C inhibitor is the only significant inhibitor of hK2 in semen. hK2 reacted more rapidly with alpha2-macroglobulin than with any other inhibitor in plasma or serum. Divalent metal ions and heparin did not appreciably affect the rate of formation of any of the hK2 complexes in serum or plasma or with purified alpha2-macroglobulin or C1-inactivator. Measurement of one or more of the hK2 forms identified here may have diagnostic or prognostic potential for prostate cancer.
人腺激肽释放酶(hK2)是一种可能的前列腺癌新标志物,与前列腺特异性抗原同源。添加到血清或血浆中的纯化hK2与内源性蛋白酶抑制剂反应,形成分子量大于350、135和80 kDa的复合物,通过免疫印迹判断,一些hK2仍保持游离状态。前两种复合物可分别被抗α2-巨球蛋白抗体和抗C1-灭活剂抗体去除,并且它们在SDS-PAGE上与hK2和纯化的α2-巨球蛋白或C1-灭活剂之间形成的复合物迁移情况相同。80 kDa的hK2复合物不能被所使用的任何抗丝氨酸蛋白酶抑制剂抗体完全去除。因此,这些复合物可能由不止一种类型的hK2复合物组成。相比之下,通过抗蛋白C抑制剂抗体基本上可从精浆中去除所有hK2复合物,这表明蛋白C抑制剂是精液中hK2的唯一重要抑制剂。与血浆或血清中的任何其他抑制剂相比,hK2与α2-巨球蛋白反应更快。二价金属离子和肝素对血清或血浆中任何hK2复合物的形成速率,或与纯化的α2-巨球蛋白或C1-灭活剂形成复合物的速率均无明显影响。此处鉴定的一种或多种hK2形式的检测可能对前列腺癌具有诊断或预后潜力。